Kornimate/medical-research-clean huggingface dataset:
effect of pentoxifylline and zinc co-administration in patients with oligoasthenoteratozoospermia

Conditions: Idiopathic Infertility

Summary: the aim of this study is to investigate the impact of co-administration of pentoxifylline and zinc sulfate on oxidative stress, apoptosis, and inflammation, sperm capacitation and parameters in infertile men.

this study will be performed as a double-blind randomized clinical trial on idiopathic infertile men (including oligoasthenosospermia, dyspnea, astheno-teratozoospermia, oligo-astheno-teratozoospermia) referred to shafa infertility clinic. patient satisfaction, non-use of contraceptives, men aged 25 to 43 years and idiopathic infertility according to who criteria (world health, 2010) are our study criteria. a food questionnaire is also taken from them to identify patients. any medication that may affect sperm production should be discontinued within three months of the study. sampling and administration of pentoxifylline and zinc: preparation and analysis of semen samples are performed according to who 2010 recommendations. semen samples are prepared by masturbating after a 3 to 5 day abstinence period. two semen samples from these men, one before and the other after the intervention, are evaluated for basic parameters. for liquefaction, semen samples are incubated for 30 to 60 minutes at 37 ° c. microscopic tests are performed to evaluate indicators such as sperm concentration in semen, motility and sperm morphology. objectives and study methods are explained to patients who meet the inclusion criteria. written consent is then obtained from the candidate. body mass index (bmi) is assessed for patients. also, at the beginning of the study, 5 cc of blood is taken from patients to measure reproductive hormones.

Eligibility criteria:
inclusion criteria: * idiopathic infertile men * have had at least one year of unprotected intercourse infertility * sperm parameters abnormality exclusion criteria: * men with varicocele * hypersensitivity to pentoxifylline \& zinc, * pelvic organic pathologies * congenital adrenal hyperplasia * thyroid dysfunction * cushing's syndrome * hyper prolactinemia * androgen secreting neoplasia * diabetes mellitus * consumption of medications affecting carbohydrate metabolism * severe hepatic * pancreatitis * kidney diseases * gallbladder diseases * patients with alcohol consumption * patients who use cigarettes and drugs
intent pilot study - enhancing adherence intentions to endocrine therapy

Conditions: Breast Cancer; Breast Cancer Female; Breast Carcinoma

Summary: this research is being done to pilot an intervention which aims to improve participants' experiences on endocrine therapy. the name of the intervention used in this research study is: endocrine therapy education program (a brief, video-based intervention)

this research study is a randomized pilot study to determine whether a brief-video based intervention program can improve experiences of endocrine therapy (et). participants will be randomized into one of two groups: group a: endocrine therapy education intervention vs. group b wait-list control group. randomization means a participant is placed into a study group by chance. the research study procedures include screening for eligibility, in-clinic visits, and survey questionnaires. participation in this research study is expected to last 3 months. it is expected that about 60 people will take part in this research study.

Eligibility criteria:
inclusion criteria: * biologically female * about to begin or just started (within four weeks of starting) an oral form of et (either tamoxifen or ai) * 18 years of age or older * english fluency for reading and writing. * computer literacy (ability to watch videos and fill out questionnaires online) exclusion criteria: * adults unable to consent * individuals with metastatic cancer * individuals who are not yet adults (infants, children, teenagers) * pregnant women * prisoners

Keywords: breast cancer breast cancer female breast carcinoma
the hypotension prediction index in major abdominal surgery

Conditions: Hypotension During Surgery

Summary: the goal of this randomized clinical trial is to compare different types of advanced hemodynamic monitoring in patients undergoing major abdominal surgery. participants undergoing major abdominal surgery will receive anesthesia with two different types of hemodynamic monitoring - group a will receive arterial pressure cardiac output algorithm with the flotrac sensor and group b will receive hemodynamic monitoring with the hypotension prediction index. the main question the study aims to answer is: • will the hypotension prediction index algorithm reduce the rate of hypotension in comparison to arterial pressure cardiac output algorithm.

the fundamental aspect of the anesthetics perioperative management is to maintain hemodynamic stability, with special attention on the avoidance or reduction of the episodes of intraoperative hypotension (ioh). the incidence of intraoperative hypotension is related to an increased rate of perioperative morbidity and mortality. even a short period of hypotension can be related to an increased risk of postoperative stroke, myocardial injury and acute kidney injury. patients undergoing major abdominal surgery are at a high-risk of ioh because such surgeries typically require more than 2h to complete and require blood transfusion or inotrope administration. hemodynamic monitoring and the use of goal directed therapy protocols helps to diminish the incidence of perioperative complications, however the hypotension management remains a reactive approach, an intervention is made when the hypotension has already occured. the hypotension prediction index is an machine learning algorithm which allows to predict the episodes of hypotension and intervene before mean arterial pressure drops below 65 mmhg. the aim of the current study is to compare the rate of hypotension in patients undergoing major abdominal surgery with the arterial pressure cardiac output algorithm and the hypotension prediction index algorithm.

Eligibility criteria:
inclusion criteria: * patients qualified to major abdominal surgery * written informed consent exclusion criteria: * patients under 18 years * lack of health insurance * pregnancy * known history of congenital heart disease, severe aortic and/or mitral stenosis, heart failure and ejection fraction \< 35 % * persistent atrial fibrillation and other arrhythmias impairing arterial pressure cardiac output monitoring

Keywords: hypotension prediction index major abdominal surgery arterial pressure cardiac output intraoperative hypotension
a study of first or second line treatment with tarceva (erlotinib) in patients with advanced non-small cell lung cancer

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Summary: this single arm study will assess the safety and efficacy of tarceva monotherapy in patients with advanced non-small cell lung cancer. patients will receive tarceva 150mg p.o. daily. the anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients \>= 18 years of age; * inoperable, locally advanced, recurrent or metastatic (stage iiib/iv) non-small cell lung cancer; * ecog performance status of 0-3; * previously untreated, or failed on one prior course of standard systemic chemotherapy and/or radiotherapy. exclusion criteria: * prior systemic anti-tumor therapy with her1/egfr inhibitors; * unstable systemic disease; * any other malignancies within 5 years (except for adequately treated cancer in situ of the cervix, or basal or squamous cell skin cancer; * any significant ophthalmologic abnormality.
treatment of cognitive impairment in men with schizophrenia (mk5757-005)(completed)

Conditions: Schizophrenia

Summary: this study is to evaluate the safety and efficacy of the study drug compared to placebo in the treatment of cognitive impairment in men with schizophrenia.


Eligibility criteria:
inclusion criteria: * patient is male between 21 and 55 years of age * duration of the illness must be longer than 1 year * patient's current antipsychotic medication regimen must be stable * patient is negative for selected drugs of abuse at screening * must be in a stable living arrangement for at least 3 months prior to screening (not a homeless shelter) exclusion criteria: * patient has mental retardation * undergone electroconvulsive therapy (ect) treatment within 6 months prior to screening * has suicidal attempts or ideation within the last 12 months * patient has a history of alcohol/drug dependence within 1 year or alcohol/drug abuse within 12 months of starting the study
an open label study to evaluate the safety and kinetics of nelfinavir in subjects with hiv and hepatitis c

Conditions: HIV Infection; Hepatitis C

Summary: the purpose of this study is to confirm the safety, efficacy and delineate the pharmacokinetic properties of nelfinavir in hiv/ hepatitis c coinfected subjects with child pugh a compensated cirrhosis and or hepatic fibrosis


Eligibility criteria:
inclusion criteria: * hiv/ hepatitic c co infected with documented hcv viremia evidence for cirrhosis and or hepatic fibrosis on liver biopsy, positive fibrosis index, stable health exclusion criteria: * decompensated cirrhosis (child pugh b or c) * pregnant or lactating women * history of previous antiretrovirals \> 14 days
the effect of the covid-19 epidemic process on the nutritional habits and body weights of adults

Conditions: COVID-19 Pandemic; Eating Habit; Weight Gain

Summary: during the covid-19 epidemic, the time spent by adults on the stomach has increased. therefore, the likelihood of adverse changes in lifestyles has increased. in this study, the changes in nutritional habits, physical activities and body weights of adult individuals during the epidemic will be evaluated. a questionnaire including questions about nutritional habits, physical activity status and changes in body weights will be administered to individuals. the results will be evaluated with the appropriate statistical method. the survey will be administered once. the estimated time to reach the total number is 3 months.


Eligibility criteria:
inclusion criteria: adult individuals wishing to participate in the study - exclusion criteria: individuals outside the age range of 19-70 years, all individuals who did not agree to participate in the study. -
use of bisphosphonates in the treatment of osteopathy after liver transplantation

Conditions: Osteoporosis; Liver Transplantation

Summary: patients with a terminal chronic liver disease have a disordered bone metabolism resulting in a higher risk of falling ill with osteoporosis. although liver transplantation restores liver function, immunosuppressive therapy (especially corticosteroids) after transplantation increases again the risk of osteoporosis and bone fragility. zoledronate, a bisphosphonate, slows down the destruction of bone. the purpose of this study is to determine whether bisphosphonates are effective in the prevention of osteoporosis following immunosuppressive therapy after liver transplantation.


Eligibility criteria:
inclusion criteria: * primary liver transplantation * retransplantation within two weeks * written informed consent * age ≥ 18 years exclusion criteria: * chronic kidney disease: * creatinine clearance \ 2,5 mg/dl * known hypersensitivity to zoledronate, or any of the recipients of the drug * bone specific medication (bisphosphonate, fluoride, calcitonin) within the last three months before liver transplantation
effect of rhbmp-2 or rhbmp-7 on long bone fractures and non-unions.

Conditions: Long Bone Non-union

Summary: delayed fracture healing continues to cause significant patient morbidity and economic burden to society. biological stimulation of acute fractures and non-unions includes application of rhbmp-2 and rhbmp-7. however, bmp use continues to be a matter of controversy as literature shows scarce evidence for treatment effectiveness. the aim of this study is to compare acute fractures and non-unions in the long bones humerus, femur and tibia with and without bmp treatment of acute fractures. furthermore, the investigators want to identify complications and risk factors on union-rate and time to union.

primary objective: the primary objective is to assess time to union and union rate after rhbmp-2 and rhbmp-7 application at long bone fractures and non-unions. secondary objective(s): * analysis of secondary complications * analysis of risk factors hypothesis and statistical considerations and estimated enrollment: the investigators hypothesize that with the use of rhbmp-2 and rhbmp-7 there will be a faster timer to union and higher union rate compared to no-bmp. outcomes will be assessed prospectively. this study is exploratory in nature. therefore, there is no formal statistical hypothesis and no formal sample size calculation. approximately 150 long-bone fractures and non-unions are expected. data will be analyzed with the use of simple summary statistics. depending on the volume and quality of the collected data, different statistical analyses will be applied. exploratory analyses will be conducted to investigate relationships between the different treatment options and the outcomes.

Eligibility criteria:
inclusion criteria: * long bone fracture or long bone non-union. * signed informed consent, if required by irb/ec exclusion criteria: prisoner at date of inclusion

Keywords: long bone non-union
a study of mirikizumab in participants with plaque psoriasis

Conditions: Psoriasis

Summary: this study is known as a "drug interaction study." the purpose is to learn how commonly used drugs or substances (midazolam, warfarin, dextromethorphan, omeprazole, and caffeine) and their breakdown products get into the bloodstream after taking a "cocktail" (combination) of them before and after multiple doses of mirikizumab. the study will last about 23 weeks for each participant. screening must be completed within 4 weeks prior to study start.


Eligibility criteria:
inclusion criteria: * males and females with chronic plaque psoriasis for at least 6 months who are candidates for systemic therapy or phototherapy * have greater than or equal to (≥) 10 percent body surface area (bsa) involvement at screening and first admission to the clinical site exclusion criteria: * pregnant or nursing (lactating) * history of an ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection * have major surgery within 8 weeks prior to first admission to the clinical site or during the study * have a history of lymphoma, leukemia, or any malignancy * require treatment with the cocktail drugs within 14 days prior to the first administration of the drug cocktail through the end of week 12 assessments * have participated in any other study with mirikizumab
translation of the "exercise in mental illness questionnaire (emiq)" to german

Conditions: Physical Activity; Psychiatric Disorder

Summary: the "the exercise in mental illness questionnaire (emiq) - health practicioners version" is a questionnaire designed to assess the prescription behaviour of physical activity as well as related knowledge, barriers and exercise behaviour of mental health professionals. as a lot of research on prescription behaviour is done using unvalidated questionnaires we want to translate this validated questionnaire into german for further use in this research field.

the "the exercise in mental illness questionnaire (emiq) - health practicioners version" is a questionnaire designed to assess the prescription behaviour of physical activity as well as related knowledge, barriers and exercise behaviour of mental health professionals. as a lot of research on prescription behaviour is done using unvalidated questionnaires we want to translate this validated questionnaire into german for further use in this research field. therefore we plan to translate the questionnaire in accordance to established questionnaire translation guidelines. then we plan to validate the questionnaire in a sample of about 30 mental health professionals (psychiatrists, psychologists, nurses) currently working with patients with mental disorders. we plan to evaluate re-test-reliability using repeated measurement within 7 days.

Eligibility criteria:
inclusion criteria: * psychiatrist, psychologist or nurse * working with patients with mental disorders * german mother language exclusion criteria: - none
insulin sensitivity and substrate metabolism in patients with cushing's syndrome

Conditions: Cushing's Syndrome; Insulin Resistance

Summary: the purpose of this study is to investigate the effect og chronic elevated levels of cortisol on metabolism and insulin sensitivity.


Eligibility criteria:
inclusion criteria: * written consent * age between 18 and 70 * diagnosed with cushing's syndrome exclusion criteria: * suspected malignancy

Keywords: cushing's syndrome glucose tolerance insulin sensitivity substrate metabolism body composition
evaluation of efficacy and safety of subcutaneous acetaminophen

Conditions: Pain; Fever; Drug Effect; Drug Reaction

Summary: subcutaneous perfusion is an underused technique, the effectiveness of which has been demonstrated. a number of drugs of different therapeutic classes, including morphine, have a good level of scientific evidence for use by this route. subcutaneous acetaminophen injection is being used in some medical centers, mainly in europe, despite the lack of definite evidence on its efficacy. this study aims to quantify the degree of effectiveness of subcutaneous acetaminophen infusions for pain or fever in geriatrics and palliative care, as well as determining its safety.

subcutaneous perfusion is an underused technique, the effectiveness of which has been demonstrated. it is mainly used in palliative care and geriatrics when a venous line is not available. it is a simple and comfortable technique that allows to administer solutes and / or medications continuously or discontinuously in the subcutaneous tissue. a number of drugs of different therapeutic classes, including morphine, have a good level of scientific evidence for use by this route. subcutaneous acetaminophen injection is being used in some medical centers, mainly in europe, despite the lack of definite evidence on its efficacy. it is sometimes accused of causing pain at the injection site; it seems that this is not the case if it is infused slowly, over 20 minutes to 30 minutes. there is no report of serious local effects. the consultation palliative care team at hôtel-dieu de france (hdf) has used subcutaneous acetaminophen infusions repeatedly without adverse effects since january 2014. this study aims to quantify the degree of effectiveness of subcutaneous acetaminophen infusions for pain or fever in geriatrics and palliative care, as well as determining its safety.

Eligibility criteria:
inclusion criteria: * patients seen by the palliative care consultation team, patients admitted in the palliative care unit, or geriatric patients (patients aged 65 and older) in participating centers in lebanon * presence of pain or fever necessitating the administration of paracetamol * absence of an intravenous line

Keywords: acetaminophen palliative care infusions, subcutaneous treatment outcome geriatrics gerontology
long-term, open label atomoxetine study

Conditions: Attention Deficit Hyperactivity Disorder

Summary: to learn about the safety and any side effects of atomoxetine when given to children and adolescents for about 5 years (long-term) and to learn whether atomoxetine can help children and adolescents with attention-deficit/hyperactivity disorder (adhd) who take the drug for about 5 years (long-term). study participants can be atomoxetine naive, atomoxetine experienced whose therapy has been interrupted or, atomoxetine experienced on a known stable dose.


Eligibility criteria:
inclusion criteria: * must be at least 6 years old but less than 18 years old when enrolled in first atomoxetine study * must meet the study criteria for adhd * must be willing to have blood drawn and to complete other test required for this study exclusion criteria: * allergic to more than 1 kind of medicine or have had multiple bad reactions to any drug * taking certain medicines that could interact with atomoxetine * plan to move too far away from a doctor participating in this study in the next 5 years * current or past history of any of the following: alcohol or drug abuse within the past 3 months, bipolar i or ii disorder, high blood pressure, organic brain disease or seizures, psychosis, other disorders or conditions diagnosed by a doctor that might make you unsuitable to participate in this study
genetic basis of melanocytic nevi

Conditions: Melanocytic Nevi

Summary: the objective of this protocol is to further elucidate the genetic mutations that drive melanocytic nevi (benign melanocytic neoplasms, moles). this will be performed by whole genome, whole exome, or targeted sequencing of de-identified specimens. herein, the investigators plan to isolate dna from de-identified skin biopsy specimens and blood samples: 1. from melanocytic nevi collected by skin biopsy (a shave or punch biopsy). a part of the tissue will be submitted for routine diagnostic dermatopathology and investigational histomorphologic and immunohistochemical analysis. 2. from corresponding normal tissue (blood). dna isolated from blood will be used as a normal control when analyzing sequencing data to identify somatic mutations in lesional tissue.


Eligibility criteria:
inclusion criteria: * male or female subjects that are 18 years or older * subjects with melanocytic nevi\\ exclusion criteria: * patients less than 18 years of age * patients without melanocytic nevi * patients with a bleeding disorder or are taking anticoagulation medication
long-term dopamine transporter imaging and clinical assessment of parkinson's disease progression

Conditions: Parkinson Disease

Summary: the purpose of this project is to assess the change in dopamine transporter density in parkinson's disease subjects during a sixty month period including a nine month treatment trial of levodopa. dopamine transporter will be assessed using \[123i\]ß-cit spect (single photon emission computed tomography) imaging, a marker of dopamine terminal integrity and of clinical disease state.

all subjects will be imaged at the institute for neurodegenerative disorders. subjects will be evaluated sequentially with \[123i\]ß-cit spect and standardized clinical rating scales during a sixty month period. the subjects involved in this study will have had \[123i\]ß-cit and spect scans at baseline and return for scanning at week 40 following the start of their participation in the elldopa study. before each spect procedure subjects will be tested to ensure eligibility for the study. they will also have a neurological evaluation including tests of motor function, thinking, memory and handwriting. some of these tests will be given with the aid of a computer. on the first day participants are injected with \[123i\]ß-cit, an investigational radioactive material that localizes in the brain. study participants will also have a thorough neurologic examination and standard neuropsychological testing, including testing of memory, concentration, abstraction and visual spatial functions. twenty-four hours later study participants return to the institute for neurodegenerative disorders where an investigational scanning procedure will be used to obtain spect (single photon emission computed tomography) images of the brain.

Eligibility criteria:
inclusion criteria: * prior participation in the study titled dopamine transporter imaging assessment of parkinson's disease progression (damd17-99-1-9472) \[123i\] b-cit and spect in vivo imaging assessment of dopamine transporter density in subjects with early parkinson's disease participating in earlier vs. later levodopa in parkinson's disease (elldopa)\]. exclusion criteria: * inability to sign informed consent and participate in all study procedures. * mini mental status exam \< 25. * pregnancy

Keywords: parkinson brain imaging